Shareholders meeting

BAFNA PHARMACEUTICALS LIMITED REGD. OFFICE: “BAFNA TOWERS”, NO.299, THAMBU CHETTY STREET, CHENNAI – 600001, TAMIL NADU, INDIA PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, Email: info@bafnapharma.com, Website: www.bafnapharma.com CIN: L24294TN1995PLCO30698 Date: August 19, 2026 BSE Limited, National Stock Exchange of India Limited, Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Bandra Kurla Complex, Mumbai - 400001. Bandra East, Mumbai – 400051. Scrip Code: 532989 Scrip Code: BAFNAPH Dear Sir / Madam, Subject: Disclosure under Regulation 34(1) of SEBI (LODR) Regulations, 2015 – Annual Report for the Financial Year 2025-2026 We hereby inform you that the 31st Annual General Meeting (AGM) of the Company will be held on Friday, September 11, 2026, at 10:00 A.M (IST) through Video Conferencing (VC) / Other Audio-Visual Means (OAVM), in accordance with the applicable provisions of the Companies Act, 2013 and the Rules made thereunder read with the applicable Circulars issued by the Ministry of Corporate Affairs (MCA) and the Securities Exchange Board of India (SEBI). The company has engaged Central Depository Services (India) Limited (“CDSL”) to provide E-Voting services and VC/OAVM facility for this AGM. Pursuant to Regulation 34(1) of the SEBI (LODR) Regulations, 2015, we herewith enclose the copy of the Annual Report for the financial year 2025-2026 and the Notice of the 31st Annual General Meeting. The Annual Report along with the Notice of the 31st Annual General Meeting are being sent to the Members through Electronic Mode and the same is also uploaded on the website of the Company at the weblink http://bafnapharma.com/financials.html. We request you take the above information on record. Thanking You. For BAFNA PHARMACEUTICALS LIMITED Mohanachandran A Company Secretary & Compliance Officer Factory: No.147, Madhavaram Redhills High Road, Grantlyon Village, Vadakarai Post, Chennai-600 052, TN, India Phone: 9445149001 Email: factory1@bafnapharma.com Building Together, For A Brighter Tomorrow CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS Building Together for a Brighter Tomorrow t Bafna Pharmaceuticals Limited, future for communities around the world. progress is built on collaborative During FY26, we progressed on our expansion strength, strategic precision, plans. We posted operating revenue of INR impeccable execution, and an 1,506 million with 3.26% growth; operating unyielding commitment to global healthcare profit of INR 159 million with 43% growth and accessibility. As we complete over three decades a net profit of INR 111 million with a staggering of operational excellence, our vision reaches far 167% growth. With a strong product pipeline, beyond boundaries. effective capacity utilization and strong By expanding our global footprint across 20+ marketing strategies, we are working towards countries, deepening our Contract Research and opportunity landscape of tomorrow. As we Manufacturing Services (CRAMS) capabilities, continue our journey forward, we are building and investing in green energy and advanced together, with all our stakeholders, for a brighter R&D, we are co-creating a sustainable, healthier tomorrow for all. ANNUAL REPORT 2025-26 1 CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS Bafna Facts Tier-1 Regulatory Accreditations Operates Chennai-based manufacturing facility certified by top global regulatory bodies, including UK-MHRA, EU-GMP, TGA-Australia, and WHO-GMP. Export-Driven Business Model Generates ~64% to 70% of total revenues through exports across 20+ countries in the UK, Europe, Australia, Asia, and Africa. First-to-Market Innovation First pharmaceutical player to launch generic Prednisolone Enteric Coated tablets in the UK. DSIR-Approved R&D Operates an in-house Formulation Research & Development (FR&D) center recognized by the Department of Scientific and Industrial Research (DSIR), Government of India. Financial Performance Reported ₹1,506.17 million in total revenue with a 167.30% YoY growth in Net Profit to ₹111.00 million. Major Industry Recognitions Awarded Emerging Company of the Year in Healthcare (2025) and holds ZED Gold Category status from the Ministry of MSME, Government of India. Credit Upgrade Credit rating revised from stable to positive by ICRA for INR 500 million credit facilities on January 23, 2026 2 ANNUAL REPORT 2025-26 CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS Long-term Loans and Cash Credit Short-term LOC Listed on: BSE (Code: 532989) and NSE (Symbol: BAFNAPH) Investor Information: http://bafnapharma.com/financials.html Investor Contact: cs@bafnapharma.com ANNUAL REPORT 2025-26 3 CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS Today’s Actions, Tomorrow’s Foundation KEY DEVELOPMENTS IN FY 2025–26 The financial year 2025–26 marked a period of operational streamlining & expansion, credit resilience, and corporate recognition for Bafna Pharmaceuticals: OPERATIONAL HIGHLIGHTS (FY 2025–26) Asset Monetization & Facility Rationalization The Company has hived-off of its manufacturing unit at Madhavaram, Chennai, enabling sharper focus on modernized core assets situated at Grantlyon, Chennai. Credit Rating Upgrade Demonstrating strong balance sheet health and debt servicing capability, ICRA revised Bafna Pharma’s credit outlook from Stable to Positive (BB+ for long-term facilities / A4+ for short- term facilities) on January 23, 2026. Healthcare Industry Recognition Honored as the “Emerging Company of the Year in Healthcare” at the MSME Global Platinum Business Excellence Awards 2025 on April 28, 2025. Promoter Equity Streamlining Promoter entity SRJR Lifesciences LLP had executed an Offer for Sale (OFS) of 13.30% voting rights, realigning promoter shareholding to 74.57% as of March 31, 2025, in compliance with applicable SEBI Regulations and thereby increasing public liquidity. 4 ANNUAL REPORT 2025-26 CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS FINANCIAL HIGHLIGHTS (FY 2025–26) Driven by export acceleration and strict operational cost control, Bafna Pharma registered robust profitability across all metrics in FY26: 1,506.17 Revenue from Operations 1,458.57 ₹1,506.17 million 3.26% (up 3.26% YoY from ₹1,458.57 million). FY 2024-25 FY 2025-26 958.10 729.78 Export Sales Growth 31.29% Surge of 31.29% to ₹958.10 million. FY 2024-25 FY 2025-26 EBITDA Expansion Reached ₹207.04 million (+48.74% YoY), pushing EBITDA 9.54% 13.75% margin from 9.54% to 13.75%. (advancing toward the target EBITDA Margin Goal of ≥15%). FY 2024-25 FY 2025-26 111.00 Net Profit (PAT) Increased by 167.30% to ₹111.00 million 41.53 167.30% (compared to ₹41.53 million in FY25). FY 2024-25 FY 2025-26 Earnings Per Share (EPS) ₹1.76 ₹4.69 Expanded to ₹4.69 from ₹1.76 in FY25. FY 2024-25 FY 2025-26 Return on Net Worth 6.86% 15.31% Improved significantly to 15.31% (vs 6.86% in FY25). FY 2024-25 FY 2025-26 Capital Discipline & Strategy Maintain minimum-debt status supported by prudent capex allocation and strict working capital control. ANNUAL REPORT 2025-26 5 CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS ANNUAL REPORT 2025-26 Visit our Investor Relations section here http://bafnapharma.com/financials.html Caution Regarding Forward-Looking Statements We have used a few forward-looking (futuristic) statements throughout the report solely to articulate our future growth prospects and to exemplify our intended milestones. However, the actual results may vary from the forward- looking statements as the business is subject to a number of risks and uncertainties according to the market scenario. For readers’ reference, we have used words like ‘anticipate’, ‘estimate’, ‘expect’, ‘project’, ‘intend’, ‘plan’, ‘believe’, and words of similar nature to signify every forward-looking statement. We do not guarantee that these statements will stand true, but we believe that these are backed up by pruden [Showing first 8,000 characters — download PDF for full document]